{"id":4603,"date":"2024-07-29T13:14:09","date_gmt":"2024-07-29T03:14:09","guid":{"rendered":"\/eu-uk\/?p=4603"},"modified":"2024-07-29T13:14:09","modified_gmt":"2024-07-29T03:14:09","slug":"orthocell-submits-singapore-regulatory-application-for-striate","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/07\/29\/orthocell-submits-singapore-regulatory-application-for-striate\/","title":{"rendered":"Orthocell submits Singapore Regulatory Application for Striate+\u2122"},"content":{"rendered":"

Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+\u2122 in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).<\/span><\/p>\n

Striate+ was recently approved in Canada and is now pending approval for sale in Singapore and Brazil in the near term. Orthocell is working with exclusive global distribution partner BioHorizons to achieve further regulatory approvals for Striate+ in multiple new large markets.<\/span><\/p>\n

The strategic partnership has resulted in significant revenue growth for Orthocell, with increasing quarterly revenue and record annual total revenue in FY24 of $6.72 million, up 30.4% from the previous year (FY23) of $5.15 million.<\/span><\/p>\n

Orthocell Managing Director, Paul Anderson, said:<\/b><\/p>\n

\u201cWe are delighted to announce our regulatory application for Striate+ in Singapore, a key strategic stepping stone into the wider ASEAN market. Our global marketing program for Striate+ is really gaining traction, and this application is a testament to our team\u2019s continued efforts to make Striate+ available to patients and dental surgeons across the world. Once Singapore and Brazil applications are approved, Striate+ will be available for sale for use in guided bone and tissue repair in seven large and attractive markets.\u201d<\/span><\/p>\n

Click here to read the ASX release.<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+\u2122 in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).<\/p>\n","protected":false},"author":2,"featured_media":4604,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t